Last $0.05 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

pacifichealth laboratories (PHLI) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
08/1/13 - $0.14
52 Week Low
11/5/13 - $0.03
Market Cap
939.2K
Average Volume 10 Days
1.5K
EPS TTM
$-0.04
Shares Outstanding
20.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIFICHEALTH LABORATORIES (PHLI)

Related News

No related news articles were found.

pacifichealth laboratories (PHLI) Related Businessweek News

No Related Businessweek News Found

pacifichealth laboratories (PHLI) Details

PacificHealth Laboratories, Inc., a nutrition company, engages in the design, development, and marketing of dietary and nutritional supplements that enhance health and well-being primarily in the United States, Canada, Singapore, South America, and the United Kingdom. It primarily focuses on sports performance and recovery, including optimal weight management. The company provides ENDUROX R4, a recovery drink; ACCELERADE sports drinks; ACCEL GEL, a sports gel; ENDUROX EXCEL dietary supplements; and 2ND SURGE, an ultra energy gel. It also offers ACCEL RECOVER, a muscle recovery bar; and ACCELERADE HYDRO sports drinks with less calories and sugar. The company markets its products through its retail outlets, including GNC, sports specialty stores, independent health food retailers, independent bike retailers, health clubs, catalogs, and Internet sites, as well as through independent distributors. PacificHealth Laboratories, Inc. was founded in 1995 and is based in Matawan, New Jersey.

8 Employees
Last Reported Date: 03/9/12
Founded in 1995

pacifichealth laboratories (PHLI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pacifichealth laboratories (PHLI) Key Developments

Pacifichealth Laboratories Inc. Files Form 15

Pacifichealth Laboratories Inc. announced that it has filed Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock of $0.0025 par value per share under the Securities Exchange Act of 1934, as amended.

Pacifichealth Laboratories Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended September 30, 2012

Pacifichealth Laboratories Inc. reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2012. Revenues were $1,721,119 for the third quarter ended September 30, 2012 compared to $1,971,624 for the same period in 2011. The company said that the biggest impact to revenue in the third quarter was the transitioning from its old formula ACCELERADE and ENDUROX R4 to its new all-natural formulas. Net loss for the third quarter of 2012 was $345,439, or $0.02 per share, compared to a net loss of $116,675, or $0.01 per share for the third quarter of 2011. Loss before other expense and provision for income taxes was $337,880 against $109,420 a year ago. Loss before provision for income taxes was $345,439 against $116,675 a year ago. For the nine months, the company's revenues were $5,701,292 compared to $5,948,461 for the same period in 2011. Net loss for the nine months of 2012 was $454,965, or $0.02 per share, compared to a net income of $2,324, or $0.00 per diluted share, for the nine months ended September 30, 2011. Loss before other expense and provision for income taxes was $439,014 against income of $13,603 a year ago. Loss before provision for income taxes was $454,965 against income of $2,324 a year ago.

Pacifichealth Laboratories Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012

Pacifichealth Laboratories Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2012. For the quarter, the company reported net product sales of $2,229,234 against $2,245,226 a year ago. Loss before provision for income taxes was $69,677 against income before provision for income taxes of $91,769 a year ago. Net loss was $69,677 against net income of $91,769 a year ago. For the six months, the company reported net product sales of $3,980,173 against $3,976,837 a year ago. Loss before provision for income taxes was $109,526 against income before provision for income taxes of $118,999 a year ago. Net loss was $109,526 or $0.01 per basic and diluted share against net income of $118,999 or $0.01 per diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHLI:US $0.05 USD 0.00

PHLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Monster Beverage Corp $65.41 USD -0.04
PepsiCo Inc $90.86 USD +1.69
Coca-Cola Co/The $40.82 USD -0.37
Procter & Gamble Co/The $80.01 USD -0.09
True Drinks Holdings Inc $0.39 USD 0.00
View Industry Companies
 

Industry Analysis

PHLI

Industry Average

Valuation PHLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIFICHEALTH LABORATORIES, please visit www.pacifichealthlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.